|
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Celgene Corporation Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital University of Virginia |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00165477 |
- The purpose of this study is to find out if the combination of lenalidomide and radiation therapy is effective in controlling tumor growth in patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.
Condition | Intervention | Phase |
Glioblastoma Gliosarcoma Malignant Gliomas |
Drug: lenalidomide Radiation: Radiation |
Phase II |
MedlinePlus related topics: | Cancer |
Drug Information available for: | Lenalidomide CC 5013 |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Phase II Study of Lenalidomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme. |
Estimated Enrollment: | 60 |
Study Start Date: | September 2005 |
Estimated Study Completion Date: | February 2009 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Dana-Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 | |||||
Massachusetts General Hospital | |||||
Boston, Massachusetts, United States, 02114 | |||||
Beth Israel Deaconess Medical Center | |||||
Boston, Massachusetts, United States, 02115 | |||||
United States, Virginia | |||||
University of Virginia | |||||
Charlottesville, Virginia, United States, 22908-0394 |
Dana-Farber Cancer Institute |
Celgene Corporation |
Beth Israel Deaconess Medical Center |
Brigham and Women's Hospital |
Massachusetts General Hospital |
University of Virginia |
Principal Investigator: | Patrick Y. Wen, MD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute ( Patrick Wen, MD ) |
Study ID Numbers: | 05-222 |
First Received: | September 9, 2005 |
Last Updated: | October 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00165477 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|